Allbirds Inc vs Crispr Therapeutics AG — how do they compare? Allbirds Inc trades at $2.59 (market cap $30.00M), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 174.3× Allbirds Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| BIRD | CRSP | |
|---|---|---|
Market Cap | $30.00M | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $76.78 |
52-Week Low | $2.21 | $44.34 |
Enterprise Value | $48.86M | $3.65B |
Trailing returns across standard periods
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →